646P A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

• Published in: Annals of oncology Vol. 35; p. S511
• Main Authors: Twelves, C.J., Banerji, U., Tap, W.D., Cook, N., Evans, T.R.J., Plummer, R., Anthoney, A., Plummer, C., Dawson, R., Loadman, P., Lahu, G., Jones, H., Kinnersley, N., Edwards, R., Gordon, G., Cranmer, L.D.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.09.2024